Moleculin Biotech is a clinical stage pharmaceutical company. Co.'s technologies include: Annamycin, an anthracycline designed to be different than existing approved anthracyclines by eliminating cardiotoxicity and avoiding the multidrug resistance mechanisms; WP1066 Portfolio, which includes WP1066 and WP1220, two of several Immune/Transcription Modulators in the portfolio designed to inhibit phosphorylated signal transducer and activator of transcription among other transcription factors associated with tumor activity, while also stimulating a natural immune response to tumors by inhibiting the errant activity of Regulatory T-Cells. We show 34 historical shares outstanding datapoints in our MBRX shares outstanding history coverage, used to compute MBRX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing MBRX market cap history over the course of time is important for investors
interested in comparing MBRX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of MBRX versus a peer is one thing; comparing
MBRX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like MBRX can fluctuate over the course of history.
With this page we aim to empower investors researching MBRX by allowing them to research the MBRX market cap history. |
Free MBRX Email Alerts:
Video: The Importance of Market Cap
